Takayasu Arteritis Clinical Trial
Official title:
VCRC Imaging Protocol for Magnetic Resonance and Positron Emission Tomography in Large-vessel Vasculitis (Takayasu's Arteritis):Development as Clinical Trial Outcome Measures
Assessing disease activity in people with Takayasu's arteritis is difficult, as most people with the disease do not exhibit visible, measurable symptoms. Combination positron emission tomography/computed axial tomography (PET/CT) is a particularly sensitive, accurate scanning method that may improve researchers' ability to evaluate people with the disease. This study will determine the effectiveness of PET/CT in assessing disease activity in people with Takayasu's arteritis.
Takayasu's arteritis is a rare inflammatory disease that affects the aorta and its branches.
The disease is much more common in females than in males, and disease onset typically occurs
between the ages of 15 and 30. People with this disease often experience general discomfort,
fatigue, fever, night sweats, weight loss, and joint pain. In the late stages of the disease,
weak arterial walls may lead to aneurysms. Many patients do not exhibit any visible symptoms
until this point, however. Because many people with Takayasu's arteritis do not have overt
disease symptoms, the assessment of disease activity is difficult. Laboratory tests can help,
but are often unreliable. Novel approaches to assessing disease activity are urgently needed
to enhance and facilitate research on Takayasu's arteritis. This study will determine the
effectiveness of combination positron emission tomography/computed axial tomography (PET/CT)
in assessing disease activity in people with Takayasu's arteritis.
Participants in this study will enroll while their disease is active. The first PET/CT scan
will take place upon study entry, while there is active disease. Participants will have a
second PET/CT scan 3 months later, and a third scan 3 months after that if there is still
active disease present. Participants will have a maximum of 3 scans unless a scan needs to be
repeated because of technical failures, though this does not often happen. If there is no
active disease at the time of the second scan, a third scan will not be done. All PET/CT
scans will be scheduled within 10 days of participants' routine MRI scans. This study will
not require any follow-up visits.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04564001 -
Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis
|
Phase 2 | |
Terminated |
NCT04882072 -
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
|
Phase 3 | |
Completed |
NCT03750929 -
Aerobic Capacity and Strength Exercise in Takayasu's Arteritis
|
N/A | |
Recruiting |
NCT04137614 -
Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis
|
N/A | |
Recruiting |
NCT02967068 -
VCRC Tissue Repository
|
||
Recruiting |
NCT05102448 -
Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis
|
Phase 4 | |
Recruiting |
NCT03893136 -
The Registry Study of Takayasu Arteritis in East China
|
||
Active, not recruiting |
NCT00006055 -
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
|
N/A | |
Completed |
NCT03096275 -
Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis
|
Phase 3 | |
Recruiting |
NCT04300686 -
A Pilot Study in Severe Patients With Takayasu Arteritis.
|
Phase 4 | |
Recruiting |
NCT04299971 -
Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients
|
Phase 4 | |
Recruiting |
NCT03192878 -
Infliximab Biosimilar in Takayasu's Arteritis
|
N/A | |
Active, not recruiting |
NCT04071691 -
PET Imaging of Giant Cell and Takayasu Arteritis
|
||
Recruiting |
NCT05904301 -
Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
|
||
Completed |
NCT02101333 -
Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis
|
Phase 3 | |
Not yet recruiting |
NCT03550781 -
Anti-inflammatory Treatment for Inactive Takayasu Arteritis
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05168475 -
Biologics in Refractory Vasculitis
|
Phase 2 | |
Completed |
NCT03956394 -
Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging
|
N/A | |
Recruiting |
NCT05151848 -
Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis
|
Phase 4 | |
Completed |
NCT03430388 -
Yellow Fever Vaccine in Patients With Rheumatic Diseases
|
N/A |